We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), boosting the price target to $57.00. Evan Seigerman has given his Hold rating due ...

Shares of Bristol Myers Squibb Co. BMY shed 0.76% to $52.40 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21% to ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $53.18, moving -0.36% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.02%.

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $52.20, reflecting a -0.38% shift from the previouse trading day's closing. This change lagged the S&P 500's daily ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...